Background and Rationale
Glucagon like peptide-1 receptor agonists (GLP-1 RAs) have been used to treat type 2 diabetes mellitus and obesity for years to reduce cardiovascular risk and manage weight[1]1.
Recent large clinical trials have shown that semaglutide reduces albuminuria, slow kidney disease progression and reduce cardiac risk in people with type 2 diabetes mellitus and chronic kidney disease, 1reducing risk of major kidney and cardiac events by about 20% [2]. The CAPTIVATE trial tests whether these drugs also improve kidney, cardiovascular and metabolic outcomes in people with chronic kidney disease of any cause.
References:
- Marso SP, Bain SC, Consoli A, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. Nov 10 2016;375(19):1834–1844. doi:10.1056/NEJMoa1607141
- Perkovic V, Tuttle KR, Rossing P, et al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. N Engl J Med. Jul 11 2024;391(2):109–121. doi:10.1056/NEJMoa2403347